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Hyperbaric Oxygen Therapy for Diabetic
Foot Wounds
Has hope hurdled hype?
“O
nemustalwayshopewhenoneisdes-
perate, and doubt when one hopes.”
Gustave Flaubert.
Hyperbaric oxygen therapy (HBOT)
has been promoted as an effective treat-
ment for diabetic foot wounds, and the
ﬁrstcontrolledtrialforthisindicationwas
reported (in Diabetes Care) over 20 years
ago (1). Advocates have suggested that
the experimentally demonstrated effects
of HBOT on improving wound tissue
hypoxia, enhancing perfusion, reducing
edema,downregulatinginﬂammatorycyto-
kines, promoting ﬁbroblast proliferation,
collagen production, and angiogenesis
make it a useful adjunct in clinical prac-
tice for “problem wounds,” such as dia-
betic foot ulcers (2,3). HBOT is also
touted for eradicating difﬁcult to treat soft
tissue and bone infections by mechanisms
that include killing microorganisms, im-
proving leukocyte and macrophage func-
tion, and enhancing the effect of
antimicrobials (4). If realized clinically,
these beneﬁcial effects, although requir-
ing expensive technology, might power-
fully reduce the risk of lower-extremity
amputation in diabetic patients with foot
wounds. Thus, rigorously assessing the
clinical effectiveness of HBOT in diabetic
footulcerationisanimportantenterprise.
But, because both patients and clinicians
arestronglymotivatedtoavoidthedevas-
tating outcome of amputation, there is a
high potential for bias in poorly designed
trials. Proof of beneﬁt requires properly
conducted clinical trials that minimize
the possibility that preexisting prejudices
will inﬂuence the allocation of patients,
diligence of foot care, or other key man-
agement decisions.
Most of the published reports on the
effect of HBOT for treating diabetic foot
wounds have been case series or nonran-
domized trials with major methodologi-
cal limitations. Although these are a poor
source of evidence, the consistency of
positive results is noteworthy. More re-
cently, several randomized controlled tri-
als have been conducted. A Cochrane
database systematic review published in
2004 concluded, based on results from
four such trials, that “HBOT signiﬁcantly
reducedtheriskofmajoramputationand
may improve the chance of healing at 1
year” but, “. . . the small number of stud-
i e s...modest numbers of patients,
methodological and reporting inadequa-
c i e s...demand a cautious interpreta-
tion”(5).Amorerecentsystematicreview
and meta-analysis that included 10 stud-
ies(6ofwhichwerenotrandomized,con-
trolled trials) concluded that HBOT
reducestheriskofamputation(oddsratio
0.24, seven studies) and increases the
likelihood of wound healing (odds ratio
10.0, six studies) (6).
Butthereareconcerns.HBOTisavail-
able in only a minority of communities, is
very expensive (a full course of treatment
in the U.S. typically costs $50,000 [Medi-
care] to $200,000 [private pay]), and is
time-consuming (an average of 60 total
hours in the chamber). Limited economic
analyses using the ﬂawed primary clinical
datahavesuggested,however,thatHBOT
is potentially cost-effective (7,8) or even
cost-saving (9). The more skeptical view
is best summarized in a counterpoint
commentary (10) on hyperbaric oxygen
treatment for diabetic foot wounds pub-
lished 4 years ago that concluded “[it] is
time that the advocates of this therapy or-
ganized large, randomized, placebo-
controlled trials to provide deﬁnitive
answers to the questions: which, if any,
patients would beneﬁt from HBOT for a
diabeticfootwound,andhowgreatisany
measurable beneﬁt?” Have there been in-
vestigations designed to answer these
questions published since that challenge,
and, speciﬁcally, has the study from
Lund, Sweden, by Lo ¨ndahl et al. (11) in
this issue of Diabetes Care provided the
proof that HBOT naysayers are seeking?
One new study that addressed this is-
sue by Duzgun et al. (12) was published
in 2008. This randomized trial compared
the effects of HBOT with standard wound
care alone on 100 patients with a diabetic
foot ulcer that had not responded to a
month of appropriate treatment. They
foundthatHBOTwasassociatedwithsta-
tistically signiﬁcantly higher rates of
wound healing (66% vs. 0%), lower rates
of operative interventions (debridement,
amputation, or skin ﬂap or graft; 16% vs.
100%), and fewer lower extremity ampu-
tations (8% vs. 82%). This study, in com-
mon with most others previously
published, had several important limita-
tions, including a lack of investigator or
patient blinding, minimal descriptions of
the types of wounds enrolled, and dispar-
itiesintreatmentallocationthatwerepre-
sumed to be by chance. Nevertheless, it
provided useful data and increased by
two-thirds the number of patients on
which the previously cited Cochrane sys-
tematic review of HBOT for diabetic
wounds reported.
The study by Lo ¨ndahl et al. (11)
builds on work their team began in the
early1990s,whentheydemonstratedina
randomized controlled study of 16 non-
diabetic patients with a nonischemic
chronic leg ulcer, that HBOT signiﬁcantly
reduced the size of the wounds during a
6-week observation period (13). This
study,unlikeallpreviousonesexceptthat
by Abidia et al. (9), was double-blinded;
allenrolledpatientsweretreatedinamul-
tiplace hyperbaric chamber, but the
masks for half the subjects delivered air
while those for the other half delivered
100% oxygen. This method, although
technically complex, allowed for a place-
bo-controlled and blinded evaluation of
HBOT, thus eliminating many of the po-
tentialconfoundersthatplaguedothertri-
als. Fortunately, the investigators kept
this design for the current trial in patients
withdiabeticfootulcers.Inthisstudy,the
authorsenrolled94diabeticpatientswith
afootulcer(Wagnergrades2–4)thathad
been present for at least 3 months and
who did not need or could not have re-
constructive vascular surgery. They ex-
cluded only those patients for whom
HBOT was contraindicated or who had a
substance abuse problem and stratiﬁed
enrolled patients by their arterial toe
blood pressure. Hyperbaric sessions were
givenfor8to10weeks(aimingfor40ses-
sions), in conjunction with appropriate
foot care provided by a multidisciplinary
diabetic foot clinic. The primary end
point was ulcer healing, properly deﬁned
as complete epithelial regeneration, and
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randomized to the two treatment groups
were similar at baseline; of note is that
overhalfhadpreviouslyhadvascularsur-
gery to the affected lower limb. It was dis-
appointing that only 56% of eligible
patients were enrolled, and only 57% of
those enrolled completed the 40 treat-
ments (although most had at least 35).
The results of the Lo ¨ndahl study
clearly support the beneﬁt of HBOT.
Complete ulcer healing at the 1-year fol-
low-up was noted in signiﬁcantly more
HBOT-treated than hyperbaric air-
treated patients (52% vs. 29% [P  0.03]
in the intention-to-treat analysis, and
61% vs. 27% [P  0.009] in the per-
protocolanalysis).Thenumberneededto
treattoavertnonhealingwasonly4.2(3.1
intheper-protocolanalysis).Amongtheir
secondary outcomes, the rates during the
study period of major amputation (4%)
and death (7%) were relatively low (for
these elderly diabetic patients with a high
prevalence of comorbidities) and were
similar for the two groups. Although pa-
tients with infected wounds (presumably
including osteomyelitis) could be en-
rolled, and 70% of the patients were
receiving oral antibiotic therapy at the
time of enrollment, the authors, unfortu-
nately, did not comment on the rates or
speed of resolution of infection in the two
groups. The rate of adverse reactions to
hyperbaric therapy in this study was no-
table; one patient died (in the HBOT
group, possibly related to treatment), 5%
had signiﬁcant barotrauma, and 6% had
symptomatic hypoglycemia (one of
whom was hospitalized), a known poten-
tial risk of HBOT.
Theauthorsofthisstudyarecertainly
tobecommendedonthestrongstudyde-
sign they used—it was fully blinded and
placebo-controlled, with concealed allo-
cation that was maintained until the end
of a 1-year follow-up period, the exclu-
sion criteria were limited, and patients
were stratiﬁed by arterial vascular status.
The number of patients enrolled was
larger than any but the methodologically
inferior study by Duzgun et al. (12).
There were, however, some important
limitations. Only 55% of potentially eligi-
ble patients were available for analysis at
the 1-year follow-up. The Wagner system
used to grade wound severity, while also
used in previous HBOT studies and by
Medicaretodetermineeligibilityfortreat-
ment, has largely been superseded by
other systems that provide more informa-
tion(14,15).Wearegivennoinformation
regarding how many patients in each
group had osteomyelitis, a clinically im-
portant variable that was neither a reason
for exclusion nor used for stratiﬁcation of
enrolled patients. The enrolled patients
were relatively unique in some ways: the
meanagewasadecadeolderthaninmost
studies of patients with diabetic foot ul-
cers, all had ulcers that had failed pro-
longed attempts at treatment, and most
had previously had vascular surgery on
the affected leg. The description of the
severity of infection in the two groups, or
how HBOT affected the resolution of in-
fection, was inadequate. There were too
few amputations to judge the effect of
HBOT on this crucial end point. No data
supporting the statement that arterial toe
blood pressure did not predict outcomes
were provided, and transcutaneous
oxymetrywouldhavebeenabettermeans
ofdeterminingadequacyofwoundperfu-
sion and oxygenation than toe pressures
(16). Finally, the authors made no at-
tempt to address the cost-effectiveness of
this expensive technology.
What are we to conclude about the
place of HBOT in treating patients with
diabetic foot wounds? It seems clear that
in a center of excellence of both HBOT
and diabetic foot care, like the one in
Lund, HBOT can help heal refractory
wounds. It is unnecessary for the great
majority of patients, however, who will
respond to appropriate wound care
(cleansing, debridement, off-loading, an-
timicrobials, as needed). But, for chronic
diabetic foot wounds that are not re-
sponding to months of appropriate ther-
apy,thepresentstudy,togetherwithmost
of those previously published, suggests
that HBOT improves long-term healing.
Although HBOT is approved in the U.S.
for treatment of chronic osteomyelitis,
there is little published support for this
treatment for treating infectious compli-
cations in the diabetic foot. The potential
beneﬁt of HBOT comes at a high ﬁnancial
cost; it would be reasonable for payers to
ask if treating four patients to deliver one
additional healed ulcer at 1 year is cost-
effective. Further randomized controlled
trials would, of course, be welcomed. In
light of the expense of conducting prop-
erly designed clinical trials, alternative
methods of assessment, such as theoreti-
cal modeling, may be helpful (17).
The study by Lo ¨ndahl et al., standing
on the shoulders of previous trials, has
placed HBOT on ﬁrmer ground. While
thisarticlemaynotbetheonetountiethe
pursestringsofhealthcarepaymentagen-
cies, it does provide cause for hope and
serves to prove that large, properly de-
signed trials are both possible and neces-
sary. Key issues that we must yet address
tobetterunderstandtheplaceofHBOTin
treating diabetic foot wounds include de-
veloping robust criteria to determine
which patients are likely to beneﬁt, deter-
mining at what point in their treatment
HBOT should be considered (or aban-
doned), and deciding which treatment
protocols are most appropriate (18). This
landmark study at last demonstrates not
only that answering these questions is
possible using standards of evidence ap-
propriate for the 21st century, but that
seeking the answers to these questions is
no longer of interest only to the hyper-
baricindustry.Theanswersareimportant
for, and eagerly awaited by, all “stake-
holders” in the diabetic foot world.
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